drugset / Trial / NCT01342913

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

NCT01342913

Phase 3 Completed 528 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.

Timeline

Start
2011-02-01
Primary completion
2011-10-01
Completion
2011-10-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticaosne Propionate 500mcg/Salmeterol 50mcg Unknown 500 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 100 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled